UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Tag: immuno-oncology

Cell therapies: opportunities and challenges

This article is republished with kind permission from BioVox.

Recent activities in the cell therapy field have prompted many investment funds to pour fresh and increasing capital into this space. In this review, we would like to share some observations and highlight a few of the questions that arise when new modalities cross the bridge from bench to bed.

Read More

Improving the selection of candidate CD8+ T cell epitopes for immunotherapy

Alongside the talks at our conferences, the poster presentations are a huge part of the knowledge sharing that takes place. We’re thrilled to be able to take a closer look at this poster from the Research & Technology Series, presented by Wim van Esch and the team at Sanquin.

Read More

Deep Learning based detection of tumor tissue compartments improves prognostic immunoprofiling in muscle-invasive bladder cancer

Worldwide, bladder cancer (BC) is the 11th most commonly diagnosed cancer. In men, BC is the 7thmost commonly diagnosed cancer worldwide.[1]Although men are more likely to develop BC than women, women present with more advanced disease and have worse survival rates.[2]

Muscle-invasive bladder cancers (MIBC) are cancers that have grown into or through the muscle layers of the bladder wall.

Dr. Katharina Nekolla and Ansh Kapil and their team applied Deep Learning enabled pathology to better understand prognostic factors in MIBC. Here we review the significance of the research and share their original poster.

Read More

Strategic screening enables effective biomarker discovery

During my eight years at the Max Planck Institute for Molecular Genetics in Berlin, I led a protein technologies group. We developed a protein expression library, and then high-content protein arrays. In total, we made arrays with 10,000 different human proteins.

Read More

Flow Cytometry: A powerful tool in drug discovery

Flow cytometry is a powerful tool in drug discovery because it provides a way to understand the drug’s mechanism of action. In order to stratify a better target for patients, you often need to know where the drug is working, and what kind of pathway it is operating along.

Read More

Why do biomarkers fail?

When conducting an experiment to identify biomarkers, it is crucial to design the experiment properly. 80-90% of all biomarker populations for the last 20 years have not and cannot be reproduced, and the main reason that biomarkers fail is that these experiments are not designed properly. In this post, I will outline two ways in which experiments are poorly designed, and then outline the technological and methodological solution in a later blog.

Read More

A 14 colour antibody panel: developing a tool and demonstrating a process

One of the frustrations I have with Flow Cytometry is when companies present their amazing new findings at conferences, and it’s quite often about TMB cells. In my case, I work on these cells perhaps 20% of the time. The rest of the time I work on cells from other parts of the human body – bone marrow, lung, bronchoalveolar lavage, spleen – and in diverse animals such as mice, rats, and even sparrow, chicken, and mosquito.

Read More

Determining the fate of cells with Flow Cytometry

The ability to measure multiple forms of cell death simultaneously represents a significant development for such techniques. I have been using antibodies and more specific forms of dyes to identify mitochondrial activity and reactive oxygen in roughly fifty populations, whereas normally it would only be able to measure one at a time. I will be discussing this work at the Flow Cytometry Congress, and it could prove enormously beneficial to drug and immunotherapy development.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive